Kulkarni Samarth 4

What Happened
Samarth Kulkarni, CEO of CRISPR Therapeutics (CRSP), reported conversion/exercise of 19,250 derivative/RSU units into common shares on March 10, 2026, and an open-market sale of 9,798 shares on March 11, 2026 at $52.80 each, generating $517,334. The filing shows the sale was made to satisfy tax withholding obligations tied to RSU vesting and was not a discretionary trade.

Key Details

• Transaction dates and prices:
  • 2026-03-10: Exercise/conversion of 19,250 derivative/RSU units into common shares (code M).
  • 2026-03-11: Open-market sale of 9,798 shares at $52.80 per share, proceeds $517,334 (code S).
• Shares owned after transaction: not specified in the filing.
• Notable footnotes:
  • F1: Some shares remain subject to a lock-up agreement with the underwriters of the issuer’s convertible notes offering.
  • F2–F4: These were restricted stock units (RSUs) granted 3/10/2023 for 77,000 shares with quarterly vesting; the reported activity relates to the vesting of the March 10, 2026 tranche.
  • F3: The 9,798-share sale was mandated by the company’s RSU Settlement Policy to cover tax withholding — it is not a discretionary sale.
• Filing timeliness: filing dated 2026-03-12 for transactions on 3/10–3/11; no indication in the filing that it was late.

Context

• This activity reflects standard RSU settlement mechanics: a tranche vested and converted to shares, and a portion was sold to cover taxes. Such mandated, non-discretionary sales are common after RSU vesting and do not necessarily signal the insider’s view on the stock.